Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 plus Furmonertinib vs Furmonertinib as first-line therapy in EGFR-mutant MET-positive unresectable locally advanced or recurrent/metastatic NSCLC
CTR20251622Phase 2Active
- Sponsor
- RemeGen
- Start
- Jun 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC108, furmonertinib in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Started Jun 2025; status: active.
02
Drugs
RC108furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251622.